- Exchange: EN Paris
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for Transgene SA (TNG)
| Open: | 10.0600 | Day's Range: | 9.7100 - 10.1500 | Volume: | 28,292 |
|---|---|---|---|---|---|
| Previous Close: | 10.0900 | 52wk Range: | 6.8000 - 10.9800 | 1-Yr Rtn: | +29.40% |
Key Statistics for TNG
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. CAC | - |
| Earnings Per Share (EUR) (ttm) | -1.3600 |
| Est. EPS (EUR) (12/2013) | -1.4630 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 314.09 |
| Shares Outstanding (M) | 31.85 |
| 30 Day Average Volume | 48,061 |
| Price/Book (mrq) | 3.1542 |
| Price/Sale (ttm) | 79.6954 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 09/12/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for TNG
Company Profile & Key Executives for TNG
Transgene S.A. is a biotechnology company. The Company develops vaccines against cancer and infectious diseases. Transgene has products under development for lung, kidney, prostate and colorectal cancers, cutaneous T-cell lymphoma, hepatitis C, malignant melanoma, and muscular dystrophy.
| Philippe ArchinardChairman/CEO | Elisabeth KeppiDeputy CEO/Dir:Compliance |
| Stephane BoisselExecutive Vice President | Nathalie AddaDir:Regulatory Affairs |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
TNG News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page